CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications

• Egile Nagusiak: St Sauver JL (Egilea), Olson JE (Egilea), Roger VL (Egilea), Nicholson WT (Egilea), Black III JL (Egilea), Takahashi PY (Egilea), Caraballo PJ (Egilea), Bell EJ (Egilea), Jacobson DJ (Egilea), Larson NB (Egilea), Bielinski SJ (Egilea)
• Formatua: Liburua
• Argitaratua: Dove Medical Press, 2017-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Jennifer L St Sauver,1,2 Janet E Olson,1,3 Veronique L Roger,1,2,4 Wayne T Nicholson,5 John L Black III,3,6 Paul Y Takahashi,7 Pedro J Caraballo,7 Elizabeth J Bell,2 Debra J Jacobson,1,2 Nicholas B Larson,1 Suzette J Bielinski,1,3 1Department of Health Sciences Research, 2Kern Center for the Science...